Germany
Japan
United Kingdom
China
APOE (Myc-DDK-tagged)-Human apolipoprotein E (APOE)
| Vector | pCMV6-Entry |
| Tag | Myc-DDK |
| Mammalian Cell Selection | Neomycin |
Products
View as table Download
APOE (untagged)-Human apolipoprotein E (APOE)
| Vector | pCMV6-AC |
| Tag | Tag Free |
| Mammalian Cell Selection | Neomycin |
Recombinant protein of human apolipoprotein E (APOE)
| Tag | C-Myc/DDK |
| Expression Host | HEK293T |
Special Offer: Get a 20% discount on this product. Use code: "MVPro20".
APOE (GFP-tagged) - Human apolipoprotein E (APOE)
| Vector | pCMV6-AC-GFP |
| Tag | TurboGFP |
| Mammalian Cell Selection | Neomycin |
- TrueORF®
Mouse Monoclonal ApoE4 Antibody (4E4)
| Applications | WB |
| Reactivities | Human |
| Conjugation | Unconjugated |
USD 1,020.00
2 Weeks
Lenti ORF particles, APOE (Myc-DDK tagged) - Human apolipoprotein E (APOE), 200ul, >10^7 TU/mL
| Vector | pLenti-C-Myc-DDK |
| Tag | Myc-DDK |
| Mammalian Cell Selection | None |
- LentiORF®
-
USD 1,020.00
5 Weeks
Lenti ORF particles, APOE (mGFP-tagged) - Human apolipoprotein E (APOE), 200ul, >10^7 TU/mL
| Vector | pLenti-C-mGFP |
| Tag | mGFP |
| Mammalian Cell Selection | None |
- LentiORF®
-
APOE (myc-DDK-tagged) - Human apolipoprotein E (APOE), transcript variant 3
| Vector | pCMV6-Entry |
| Tag | Myc-DDK |
| Mammalian Cell Selection | Neomycin |
- TrueORF®
APOE (myc-DDK-tagged) - Human apolipoprotein E (APOE), transcript variant 4
| Vector | pCMV6-Entry |
| Tag | Myc-DDK |
| Mammalian Cell Selection | Neomycin |
- TrueORF®
APOE (myc-DDK-tagged) - Human apolipoprotein E (APOE), transcript variant 5
| Vector | pCMV6-Entry |
| Tag | Myc-DDK |
| Mammalian Cell Selection | Neomycin |
- TrueORF®
Lenti ORF clone of Human apolipoprotein E (APOE), Myc-DDK-tagged
| Vector | pLenti-C-Myc-DDK-P2A-Puro |
| Tag | Myc-DDK |
| Mammalian Cell Selection | Puromycin |
- LentiORF®
USD 1,020.00
2 Weeks
Lenti ORF particles, APOE (mGFP-tagged) - Human apolipoprotein E (APOE), 200ul, >10^7 TU/mL
| Vector | pLenti-C-mGFP-P2A-Puro |
| Tag | mGFP |
| Mammalian Cell Selection | Puromycin |
- LentiORF®
-
APOE (myc-DDK-tagged) - Human apolipoprotein E (APOE), transcript variant 1
| Vector | pCMV6-Entry |
| Tag | Myc-DDK |
| Mammalian Cell Selection | Neomycin |
- TrueORF®
Purified recombinant protein of Human apolipoprotein E (APOE).
| Tag | Tag Free |
| Expression Host | E. coli |
USD 1,020.00
2 Weeks
Lenti ORF particles, APOE (Myc-DDK tagged) - Human apolipoprotein E (APOE), 200ul, >10^7 TU/mL
| Vector | pLenti-C-Myc-DDK-P2A-Puro |
| Tag | Myc-DDK |
| Mammalian Cell Selection | Puromycin |
- LentiORF®
-
APOE MS Standard C13 and N15-labeled recombinant protein (NP_000032)
| Tag | C-Myc/DDK |
| Expression Host | HEK293 |
Goat Polyclonal Antibody against APOE
| Applications | WB |
| Reactivities | Human |
| Conjugation | Unconjugated |
| Immunogen | Peptide with sequence C-VGTSAAPVPSDNH, from the C Terminus of the protein sequence according to NP_000032.1. |
Purified recombinant protein of Human apolipoprotein E (APOE).
| Tag | Tag Free |
| Expression Host | E. coli |
Transient overexpression lysate of apolipoprotein E (APOE)
| Tag | C-Myc/DDK |
| Expression Host | HEK293T |
| Applications | WB |
Rabbit polyclonal APOE antibody
| Applications | WB |
| Reactivities | Human, Mouse, Rat |
| Conjugation | Unconjugated |
| Immunogen | The antiserum was produced against synthesized peptide derived from C-terminal of human APOE. |
APOE HEK293T cell transient overexpression lysate (as WB positive control)
| Tag | C-Myc/DDK |
| Expression Host | HEK293T |
| Applications | WB |
Lenti ORF clone of Human apolipoprotein E (APOE), mGFP tagged
| Vector | pLenti-C-mGFP |
| Tag | mGFP |
| Mammalian Cell Selection | None |
- LentiORF®
APOE (untagged) - Human apolipoprotein E (APOE), transcript variant 5
| Vector | pCMV6-AC |
| Tag | Tag Free |
| Mammalian Cell Selection | Neomycin |
APOE (untagged) - Human apolipoprotein E (APOE), transcript variant 1
| Vector | PCMV6-Neo |
| Tag | Tag Free |
| Mammalian Cell Selection | Neomycin |
Rabbit Polyclonal Antibody against APOE (C-term)
| Applications | IHC, WB |
| Reactivities | Human |
| Conjugation | Unconjugated |
| Immunogen | This APOE antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 263-292 amino acids from the C-terminal region of human APOE. |
Apolipoprotein E (APOE) mouse monoclonal antibody, clone IB5-E1, Aff - Purified
| Applications | ELISA, WB |
| Reactivities | Human |
Apolipoprotein E (APOE) mouse monoclonal antibody, clone E3, Aff - Purified
| Applications | ELISA, WB |
| Reactivities | Human |
Rabbit polyclonal anti-ApoE4 antibody
| Applications | WB |
| Reactivities | Human |
| Conjugation | Unconjugated |
| Immunogen | Recombinant human ApoE4 |
Apolipoprotein E / Apo E human protein, 50 µg
| Protein Source | Plasma |
Carrier-free (BSA/glycerol-free) APOE mouse monoclonal antibody, clone OTI6B9 (formerly 6B9)
| Applications | WB |
| Reactivities | Human |
| Conjugation | Unconjugated |
Carrier-free (BSA/glycerol-free) APOE mouse monoclonal antibody, clone OTI3C1 (formerly 3C1)
| Applications | WB |
| Reactivities | Human |
| Conjugation | Unconjugated |
APOE (GFP-tagged) - Human apolipoprotein E (APOE), transcript variant 3
| Vector | pCMV6-AC-GFP |
| Tag | TurboGFP |
| Mammalian Cell Selection | Neomycin |
- TrueORF®
APOE (GFP-tagged) - Human apolipoprotein E (APOE), transcript variant 4
| Vector | pCMV6-AC-GFP |
| Tag | TurboGFP |
| Mammalian Cell Selection | Neomycin |
- TrueORF®
APOE (GFP-tagged) - Human apolipoprotein E (APOE), transcript variant 5
| Vector | pCMV6-AC-GFP |
| Tag | TurboGFP |
| Mammalian Cell Selection | Neomycin |
- TrueORF®
APOE (GFP-tagged) - Human apolipoprotein E (APOE), transcript variant 1
| Vector | pCMV6-AC-GFP |
| Tag | TurboGFP |
| Mammalian Cell Selection | Neomycin |
- TrueORF®
APOE (untagged) - Human apolipoprotein E (APOE), transcript variant 3
| Vector | pCMV6 series |
| Tag | Tag Free |
APOE (untagged) - Human apolipoprotein E (APOE), transcript variant 4
| Vector | pCMV6 series |
| Tag | Tag Free |
Active filters
Target Symbol
- APOE
Families
- Stem cell - Pluripotency